ALPMY News and Press, Astellas Pharma Inc. ADR From 02/12/21

Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy - Durable Tumor Responses Experienced Among Patients Previ...

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer - Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and P...

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...

Astellas' XOSPATA® (gilteritinib) Receives Conditional Approval by China's National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation - Accelerated approval follows priority review designation and inclusion in overseas ne...

Astellas Pharma Inc (ALPMF) Q3 2021 Earnings Conference Call January 29, 2021 2:00 AM ET Company Participants Naoki Okamura – Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Yukio Matsui – Chief Commercial Officer Mike Kitagawa – Dev...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Astellas Pharma Inc. 2021 Q3 - Results - Earnings Call Presentation

Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year PR Newswire NORTHBROOK, Ill. , Jan. 28, 2021 /PRNewswire/ -- For the seventh consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's ...

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies - Builds the collaboration utilizing Actinium's Antibody Warhead Enabling (AWE) Technology Platform with selected Astellas targeting agents PR Newswire ...

FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients PR Newswire TOKYO , Jan. 6, 2021 /PRNewswire/ -- Astellas Pharma ...

FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline consists of two late-stage/commercialized therapeutics and one medical product all with seve...